Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Gilead Plots A Massive Move Into Oncology: A Third Of Sales By 2030

Gilead expects a third of sales to come from its cancer treatments by 2030, and GILD stock jumped Friday despite a mixed earnings report.

Investors Business Daily

2 Must-Have Pharma Stocks to Buy in August, 1 to Sell

The pharmaceutical industry is poised to thrive amid increasing global healthcare demand. Hence, two quality pharma stocks, Johnson & Johnson (JNJ) and Novartis AG (NVS), could be solid portfolio additions. However, avoiding fundamentally weak stock SNDL Inc. (SNDL) could be a wise choice. Read more.

StockNews.com

Which is the Better Value Stock for August: Catalyst Pharmaceuticals, Inc. (CPRX) vs. Teva Pharmaceutical Industries (TEVA)?

Fueled by steady demand, the pharmaceutical sector has shown resilience and expansion even in an uncertain economic environment. Amid this scenario, Catalyst Pharmaceuticals (CPRX) and Teva Pharmaceuticals (TEVA) are set to reap the rewards. However, which of the two is the better value stock for August? Read more to find…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work.

The biggest names in Covid are updating their vaccines for a fall campaign, but that might not bolster Pfizer stock and Moderna stock.

Investors Business Daily

Are These Biotech Stocks a Buy or Sell for August: Bionano Genomics (BNGO) vs. Cidara Therapeutics (CDTX)?

Underpinned by undeniable growth trends of an aging population, breakthrough therapies, and the inelastic demand for healthcare products and medicines, the biotech industry is expected to perform well in the near term. Given this backdrop, let’s compare two biotech stocks, Bionano Genomics (BNGO) and Cidara Therapeutics (CDTX), to determine if…

StockNews.com

Is Johnson & Johnson (JNJ) a Must-Buy Stability Stock?

Thanks to the company’s solid first-quarter performance and growing pharmaceutical demand, Johnson & Johnson’s (JNJ) long-term prospects look bright. However, could the company ensure stability for investors amid the current market volatility? Keep reading….

StockNews.com

Dangerous diseases found in illegal California medical lab with nearly 1,000 bioengineered mice

Police are still investigating the lab’s origins

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Biotech company settles lawsuit for profiting off of woman’s cloned cells for seven decades

Henrietta Lacks’ unique ‘Hela’ cells played a crucial role in the development of Covid-19 vaccines and treatments for HIV, leukemia and cancer

The Independent UK

Merck Outplays The Covid Decline, But Prometheus Buyout Weighs On Profits

Merck topped second-quarter expectations Tuesday, though it reported a per-share loss. Merck stock toed the line in response.

Investors Business Daily

Brain fog and other long COVID symptoms are the focus of new small treatment studies

The National Institutes of Health is starting some studies to test possible treatments for long COVID

The Independent UK

Centene Corporation’s Profits Heavily In Healthcare On Their Second Quarter Profits

The company reported a quarterly revenue of $33.71 billion and a net profit of $1.06 billion in their latest earnings release

Zenger

What's a fair price for a prescription drug? Medicare's about to weigh in

Medicare soon will start something it hasn't done in its 58-year history: Negotiate on drug prices. On Sept. 1, Medicare will target the first 10 drugs for price negotiations.

WEKU

Top 3 Pharma Stocks You Can’t Miss out On

The ever-transforming pharmaceuticals sector is ready to seize the opportunity to address the growing demand for healthcare across the globe. Therefore, adding these three quality pharma stocks, Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), and Dr. Reddy's Laboratories (RDY), to your portfolio could prove to be beneficial. Read…

StockNews.com

Edwards Lifesciences Sinks Despite An Earnings Beat, Outlook Increase

Edwards Lifesciences stock fell late Wednesday after the medtech company reported Q2 earnings, narrowly topping profit and revenue expectations.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Argenx Beats Earnings Expectations As Sales Of 'Megabuster' Drug Grow 260%

Argenx is up around 40% in 2023. On Thursday, the company reported second-quarter revenue ballooning 230% as sales of its lone product ramp up.

Investors Business Daily

Pharma Giant GSK Beats Second-Quarter Goals On Growth In Vaccines, General Medicines

Pharmaceutical giant GSK beat expectations for the second quarter and raised its forecast for the full year.

The Independent UK

Court says OxyContin maker's bankruptcy and protections for Sackler family members can move ahead

OxyContin maker Purdue Pharma can start its transformation under a bankruptcy agreement that allows the members of the wealthy Sackler family who own the company to avoid civil lawsuits over the opioid crisis, a court has ruled

StockNews.com

Is AbbVie (ABBV) a Better Stock to Buy Than Pfizer (PFE)?

Due to the emergence of new technologies and the introduction of generic medicines, the pharma industry seems well-positioned to witness growth. While pharma stocks should benefit from the industry tailwinds, let us analyze whether AbbVie (ABBV) is a better buy than Pfizer (PFE).

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Nigel Farage says NatWest management ‘should go’ after CEO Rose admits discussing his bank account with BBC – as it happened

Dame Alison Rose admitted to serious error in discussing Nigel Farage’s relationship with Coutts with a BBC journalist.

Investors Business Daily

Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates

Biogen stock dropped Tuesday after the biotechnology firm said it's eliminating 1,000 jobs as part of a strategy to cut operating expenses.

The Hindu

Explained | Will generic supply of bedaquiline be accessible?

J&J's patent on bedaquiline expired, allowing generic manufacturers to supply the drug. J&J has filed secondary patents. Prices are expected to reduce 3-6x, but some countries are excluded from the deal, raising concerns.

The Independent UK

Tornado damage to Pfizer plant unlikely to cause major drug supply shortages, FDA says

A tornado that tore through eastern North Carolina and struck a large Pfizer pharmaceutical plant has damaged its drug storage facility but not its medicine production areas

Investors Business Daily

Novo Nordisk Stock Today: This Diagonal Calendar Spread Trade Has Limited Risk, Unlimited Profit Potential

Concerns of weight loss and Type 1 diabetes are fueling the rise of our choice for this week's option position in shares of Novo Nordisk.

Chicago Tribune

Abbott’s COVID-19 test sales dive by nearly 90%

Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on from the pandemic.

StockNews.com

Are These 3 Medical Stocks a Safe Investment?

The future of the medical devices and equipment industry looks buoyant, given rising chronic conditions and the adoption of advanced technology. Given this backdrop, would it be prudent for investors to buy medical stocks, Terumo Corporation (TRUMY), Haemonetics Corp. (HAE), and MiMedx Group (MDXG)? Read more to find out….

1 … 42 43 44 45

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

International Monetary Fund

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.